DB
YMAB

Danske Bank’s Y-mAbs Therapeutics YMAB Stock Holding History

Danske Bank’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,276
Closed -$15.4K – 1674
2024
Q2 		$15.4K Hold
1,276
– – ﹤0.01% 1076
2024
Q1 		$20.7K Buy
+1,276
New +$17.2K ﹤0.01% 1015

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Danske Bank's YMAB Position: Q3 2024 in Review

Danske Bank sold out of Y-mAbs Therapeutics (YMAB) in Q3 2024, closing a stake of 1,276 shares — an estimated $15.4K sold.

Danske Bank first reported a position in YMAB in Q1 2024 and held it in 2 quarters. The position peaked at $20.7K in Q1 2024. 105 funds tracked by Wall St. Rank hold YMAB as of Q3 2024.

  • Danske Bank reported no remaining Y-mAbs Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Danske Bank sold 1,276 Y-mAbs Therapeutics shares in Q3 2024, an estimated $15.4K.
  • Danske Bank first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 2 quarters.
  • Danske Bank's Y-mAbs Therapeutics position peaked at $20.7K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2024.

Based on Danske Bank's 13F filing for Q3 2024, filed 18 Mar 2026.